The life science and biotech PR distribution service

Selvita Announces Successful Completion of $41 M Book Building

Selvita logo newest InnerValue logo


Krakow, Poland, February 16, 2018 / B3C newswire / -- Selvita (WSE:SLV), one of the largest drug discovery companies in Europe, has received investment declarations implicating placement of all 2,200,000 shares offered in the H series public subscription. The issue price was set at the previously announced maximum limit of PLN 61.00 per share. The amount of gross proceeds raised in the offering, before estimated expenses of the offering, is approximately PLN 134.2 million ($40.57 million). The funds raised in the offering will let the company implement the development strategy announced for the years 2017-2021. The offering has been co-managed by Vestor Dom Maklerski and Bank Zachodni WBK Stock Brokers. The legal advisory has been provided by Chabasiewicz, Kowalska and Partners and communications have been managed by InnerValue investor relations agency.

"We have seen strong interest in our secondary share offering. The demand for Selvita shares at the maximum price was significantly higher than the number of shares offered. We are glad to see many of the current shareholders interested in increasing their stake in Selvita, as well as welcome new strong capital market funds to our shareholder base" says Pawel Przewiezlikowski, co-founder, the largest shareholder and CEO of Selvita. "Our pipeline has progressed significantly and the services segment has been growing at more than 30% for past several years with a growing loyal client base. It is time for Selvita to speed up the company development towards later stages of clinical development and high value-added integrated project collaborations."

Apart from establishing the issue price and the final number of shares offered, the Management Board of Selvita has also determined the number of shares offered in each investor tranche. The number of shares offered to institutions will be 2,172,565 and the number of shares for retail investors will be 27,435. The subscription in the retail tranche was completed on February 14, 2018 and the institutional order book was closed on February 15, 2018. The shares in both tranches will be allocated until February 26, 2018.

The investment prospectus with ancillary documents is available on Selvita www.selvita.com/pl, Vestor  (www.vestor.pl) and Bank Zachodni WBK (www.dmbzwbk.pl) stock broker websites.

According to the strategy announced in 2017 the company will invest PLN390 million ($118 million) over the next four years in its research pipeline, new services and laboratory infrastructure. The investments will be financed by existing financial resources, cash from business activities (service revenues, partnering milestones and research funding in collaborations),  proceeds from the share issue and government grants which have already been awarded to Selvita.

The major investments planned include a new research facility which will allow Selvita service and internal pipeline part to expand to 770 people from the current 446, develop of the first-in-class CDK8 inhibitor SEL120 in acute myeloid leukemia until Phase II studies, delivery of several new oncology candidates from the Targeted Therapeutics, Cancer Metabolism and Immunometabolism as well as Immunology Platforms to Phase I studies and introduce a new platform for biologic drugs.

About Selvita
Selvita is a drug discovery company, developing breakthrough therapies in the area of oncology. The company’s most advanced program, SEL24, has been licensed to Menarini Group and is currently in Phase I studies in AML. Other projects include SEL120, a first-in-class small molecule inhibitor of CDK8 in preclinical studies, several drug discovery platforms in immuno-oncology, immunometabolism and cancer metabolism, as well as epigenetics, performed independently or in collaboration with global pharma and biotech companies.

Selvita also offers a broad range of integrated drug discovery services, helping biotech and pharma partners discover and develop new drugs.

The company has alliances and partnerships with more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe, including R&D partnerships with Menarini Group, Leukemia and Lymphoma Society, Merck, H3 Biomedicine, and Nodthera.

The company was established in 2007 and currently employs over 446 scientists, among which 30% are PhDs. Selvita is headquartered in Krakow with second research site in Poznan, Poland and international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE:SLV).


This document is for promotional purposes only.

The Prospectus is the sole legally binding document containing information about the Company and Public Offering. The Prospectus, which was published on February 1, 2018 and can be obtained from the website of the Company www.selvita.com/pl , Vestor Dom Maklerski with its registered office in Warszawa www.vestor.pl  and Bank Zachodni WBK S.A. with its registered office in Wroclaw www.dmbzbk.pl.

This document and the information in the document may not be disseminated, published or distributed, directly or indirectly, in its entirety or in parts thereof, on the territory of the United States of America, Australia, Canada or Japan.

This document does not constitute information about any securities and the terms of purchase or  subscribe for any securities, which would be sufficient grounds for the decision to purchase or to subscribe for any securities. This document does not constitute or form part of an offer or invitation or inducement to engage in investment activity to purchase or to subscribe for any securities.

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the impact of general economic, industry or political conditions in Poland or internationally. You should not place undue reliance on these forward-looking statements. Additional risks and uncertainties relating to the offering, Selvita and its business can be found under the caption “Risk Factors” included in Selvita’s investment prospectus and other filings that Selvita may make with the Polish Financial Supervisory Authority in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Selvita expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.


Piotr Ksiazek
+48 501 988 693
This email address is being protected from spambots. You need JavaScript enabled to view it.

Malgorzata Syjud
+48 660 797 362
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.